Literature DB >> 17093994

Total and free mycophenolic acid and its 7-O-glucuronide metabolite in Chinese adult renal transplant patients: pharmacokinetics and application of limited sampling strategies.

Zheng Jiao1, Jian-Yong Zhong, Ming Zhang, Xiao-Jin Shi, Yun-Qiu Yu, Wei-Yue Lu.   

Abstract

OBJECTIVE: This study aimed to investigate the pharmacokinetic characteristics of total and free mycophnolic acid (MPA) and its 7-O-glucuronide metabolite (MPAG) in Chinese renal transplant recipients. In addition, limited sampling strategies were developed to estimate the individual area under concentration curve (AUC) of total and free MPA.
METHODS: Total and free MPA and MPAG concentrations were determined by high performance liquid chromatography. Whole 12-h pharmacokinetic profiles were obtained on the 10th day after operation in 12 adult Chinese de novo renal transplant recipients administrated with mycophenolate mofetil (MMF, 750 mg bid), cyclosporine and corticosteroids. Limited sampling strategies with jackknife technique, a resampling method, and Bland-Altman analysis were employed to develop equations to estimate total and free MPA AUC.
RESULTS: The pattern of total and free MPA and MPAG plasma concentration-time curves in the cohort of patients taking lower doses of MMF was consistent with previous reports of Caucasian patients taking MMF 1 g bid, except that dose-normalized exposure of total and free MPAG was much lower in the current study than in those of the Caucasians. The mean C (max) and AUC(0-12h) of total and free MPA were 9.4 +/- 3.4 mg/L, 20.2 +/- 6.5 mg x h/L and 0.4 +/- 0.4 mg/L, 0.7 +/- 0.5 mg x h/L, respectively, whereas mean C (max) and AUC(0-12h) of total and free MPAG were 97.3 +/- 32.6 mg/L, 656.0 +/- 148.0 mg.h/L and 29.9 +/- 8.5 mg/L, 222.0 +/- 58.1 mg x h/L respectively. The mean fractions of free MPA and MPAG were 3.5 +/- 2.0 and 34.6 +/- 8.0%, respectively. No determinant was identified to influence the pharmacokinetics of total and free MPA and MPAG or the free fraction of MPA and MPAG. The combinations of C (2h)-C (4h) and C (1h)-C (2h)-C (3h) were the best to estimate free and total MPA AUC(0-12h) respectively, whereas the combination of C (2h)-C (3h)-C (4h) and C (1h)-C (2h)-C (4h) was the best to estimate both simultaneously.
CONCLUSION: This is the first time that the pharmacokinetics profile of total and free MPA and its main metabolite MPAG has been examined in Chinese adult renal transplant patients. The limited sampling strategies proposed to estimate individual free and total MPA AUC could be useful in optimizing patient care.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17093994     DOI: 10.1007/s00228-006-0215-y

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  53 in total

1.  Intravenous mycophenolate mofetil: safety, tolerability, and pharmacokinetics.

Authors:  M D Pescovitz; D Conti; J Dunn; T Gonwa; P Halloran; H Sollinger; S Tomlanovich; S Weinstein; S Inokuchi; B Kiberd; D Kittur; R M Merion; D Norman; A Shoker; R Wilburn; A J Nicholls; S Arterburn; E Dumont
Journal:  Clin Transplant       Date:  2000-06       Impact factor: 2.863

Review 2.  Therapeutic drug monitoring of mycophenolate mofetil in transplantation.

Authors:  Teun van Gelder; Yann Le Meur; Leslie M Shaw; Michael Oellerich; David DeNofrio; Curtis Holt; David W Holt; Bruce Kaplan; Dirk Kuypers; Bruno Meiser; Burkhard Toenshoff; Richard D Mamelok
Journal:  Ther Drug Monit       Date:  2006-04       Impact factor: 3.681

Review 3.  Influence of race or ethnicity on pharmacokinetics of drugs.

Authors:  J A Johnson
Journal:  J Pharm Sci       Date:  1997-12       Impact factor: 3.534

Review 4.  Pharmacokinetic and metabolic investigations of mycophenolic acid in pediatric patients after renal transplantation: implications for therapeutic drug monitoring. German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients.

Authors:  M Oellerich; M Shipkova; E Schütz; E Wieland; L Weber; B Tönshoff; V W Armstrong
Journal:  Ther Drug Monit       Date:  2000-02       Impact factor: 3.681

Review 5.  The design and development of an immunosuppressive drug, mycophenolate mofetil.

Authors:  A C Allison; E M Eugui
Journal:  Springer Semin Immunopathol       Date:  1993

6.  Characterizing the role of enterohepatic recycling in the interactions between mycophenolate mofetil and calcineurin inhibitors in renal transplant patients by pharmacokinetic modelling.

Authors:  Serge Cremers; Rik Schoemaker; Eduard Scholten; Jan den Hartigh; Jacqueline König-Quartel; Eric van Kan; Leendert Paul; Johan de Fijter
Journal:  Br J Clin Pharmacol       Date:  2005-09       Impact factor: 4.335

7.  Mycophenolic acid pharmacokinetics and related outcomes early after renal transplant.

Authors:  Bronwyn A Atcheson; Paul J Taylor; David W Mudge; David W Johnson; Carmel M Hawley; Scott B Campbell; Nicole M Isbel; Peter I Pillans; Susan E Tett
Journal:  Br J Clin Pharmacol       Date:  2005-03       Impact factor: 4.335

8.  Automated determination of free mycophenolic acid and its glucuronide in plasma from renal allograft recipients.

Authors:  Randeep Mandla; Pål-Dag Line; Karsten Midtvedt; Stein Bergan
Journal:  Ther Drug Monit       Date:  2003-06       Impact factor: 3.681

Review 9.  Clinical pharmacokinetics of mycophenolate mofetil.

Authors:  R E Bullingham; A J Nicholls; B R Kamm
Journal:  Clin Pharmacokinet       Date:  1998-06       Impact factor: 6.447

10.  Free mycophenolic acid should be monitored in renal transplant recipients with hypoalbuminemia.

Authors:  Bronwyn A Atcheson; Paul J Taylor; Carl M J Kirkpatrick; Stephen B Duffull; David W Mudge; Peter I Pillans; David W Johnson; Susan E Tett
Journal:  Ther Drug Monit       Date:  2004-06       Impact factor: 3.681

View more
  11 in total

1.  Limited sampling strategy models for estimating the AUC of gliclazide in Chinese healthy volunteers.

Authors:  Ji-Han Huang; Kun Wang; Xiao-Hui Huang; Ying-Chun He; Lu-Jin Li; Yu-Cheng Sheng; Juan Yang; Qing-Shan Zheng
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2012-05-26       Impact factor: 2.441

2.  Population pharmacokinetics of mycophenolic acid in lung transplant recipients with and without cystic fibrosis.

Authors:  Xiao-Xing Wang; Meihua R Feng; Hugh Nguyen; David E Smith; Diane M Cibrik; Jeong M Park
Journal:  Eur J Clin Pharmacol       Date:  2015-05-07       Impact factor: 2.953

3.  Population pharmacokinetics of mycophenolic acid and its main glucuronide metabolite: a comparison between healthy Chinese and Caucasian subjects receiving mycophenolate mofetil.

Authors:  Jing Ling; Jun Shi; Qiudi Jiang; Zheng Jiao
Journal:  Eur J Clin Pharmacol       Date:  2014-10-21       Impact factor: 2.953

4.  Significant Correlations between p-Cresol Sulfate and Mycophenolic Acid Plasma Concentrations in Adult Kidney Transplant Recipients.

Authors:  Yan Rong; Penny Colbourne; Sita Gourishankar; Tony K L Kiang
Journal:  Clin Drug Investig       Date:  2022-02-18       Impact factor: 2.859

Review 5.  How accurate and precise are limited sampling strategies in estimating exposure to mycophenolic acid in people with autoimmune disease?

Authors:  Azrin N Abd Rahman; Susan E Tett; Christine E Staatz
Journal:  Clin Pharmacokinet       Date:  2014-03       Impact factor: 6.447

6.  Pharmacokinetic role of protein binding of mycophenolic acid and its glucuronide metabolite in renal transplant recipients.

Authors:  Brenda C M de Winter; Teun van Gelder; Ferdi Sombogaard; Leslie M Shaw; Reinier M van Hest; Ron A A Mathot
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-11-11       Impact factor: 2.745

7.  Population pharmacokinetic modelling for enterohepatic circulation of mycophenolic acid in healthy Chinese and the influence of polymorphisms in UGT1A9.

Authors:  Zheng Jiao; Jun-Jie Ding; Jie Shen; Hui-Qi Liang; Long-Jin Zhong; Yi Wang; Ming-Kang Zhong; Wei-Yue Lu
Journal:  Br J Clin Pharmacol       Date:  2008-02-15       Impact factor: 4.335

8.  Limited Sampling Strategy for Estimation of Mycophenolic Acid Exposure in Adult Chinese Heart Transplant Recipients.

Authors:  Hongping Xiang; Hong Zhou; Jing Zhang; Yongfeng Sun; Yirong Wang; Yong Han; Jie Cai
Journal:  Front Pharmacol       Date:  2021-04-12       Impact factor: 5.810

9.  The Evaluation of Multiple Linear Regression-Based Limited Sampling Strategies for Mycophenolic Acid in Children with Nephrotic Syndrome.

Authors:  Joanna Sobiak; Matylda Resztak; Maria Chrzanowska; Jacek Zachwieja; Danuta Ostalska-Nowicka
Journal:  Molecules       Date:  2021-06-18       Impact factor: 4.411

10.  Effect of Protein Binding on Exposure of Unbound and Total Mycophenolic Acid: A Population Pharmacokinetic Analysis in Chinese Adult Kidney Transplant Recipients.

Authors:  Changcheng Sheng; Qun Zhao; Wanjie Niu; Xiaoyan Qiu; Ming Zhang; Zheng Jiao
Journal:  Front Pharmacol       Date:  2020-03-20       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.